文献速递乳腺癌

氟维司群联合依维莫司或安慰剂治疗内分泌耐药转移性乳腺癌的随机II期试验:PrE0102结果

Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102.
PubMed 文献 · J Clin Oncol · 2018-04-17

PrE0102研究纳入131例绝经后激素受体阳性、HER2阴性、芳香化酶抑制剂耐药的转移性乳腺癌患者,随机接受氟维司群联合依维莫司或安慰剂。

要点

  • 依维莫司联合氟维司群显著改善AI耐药患者的PFS(10.3 vs 5.1个月,HR 0.61)。
  • 联合组临床获益率显著更高(63.6% vs 41.5%),但客观缓解率无显著差异。
  • 联合组不良反应更常见,包括口腔炎、乏力、皮疹等,但3-4级事件不常见。

核心结论

  • 依维莫司可增强氟维司群在AI耐药、ER阳性转移性乳腺癌中的疗效。

研究设计与样本

  • 随机、双盲、安慰剂对照的II期研究,纳入131例绝经后ER阳性、HER2阴性、AI耐药的转移性乳腺癌患者。
  • 患者随机分配至氟维司群(500 mg,第1周期第1和15天,后续周期第1天)联合依维莫司或安慰剂组。
  • 研究设计有90%把握度检测中位PFS从5.4个月至9.2个月的70%改善。

主要发现

  • 依维莫司组所有级别不良事件更常见,包括口腔炎(53% vs 12%)、乏力(42% vs 22%)、皮疹(38% vs 5%)、贫血(31% vs 6%)、腹泻(23% vs 8%)、高血糖(19% vs 5%)、高甘油三酯血症(17% vs 3%)和肺炎(17% vs 0%),但3-4级事件不常见。

关键数值与推荐

  • 未使用预防性皮质类固醇漱口水。

临床怎么用

  • 对于AI耐药的ER阳性、HER2阴性转移性乳腺癌患者,可考虑氟维司群联合依维莫司以改善PFS和临床获益率。
  • 需注意监测和管理依维莫司相关不良事件,如口腔炎、乏力、皮疹、贫血、腹泻、高血糖、高甘油三酯血症和肺炎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Purpose The mammalian target of rapamycin inhibitor everolimus targets aberrant signaling through the PI3K/AKT/mammalian target of rapamycin pathway, a mechanism of resistance to anti-estrogen therapy in estrogen receptor (ER)-positive breast cancer. We hypothesized that everolimus plus the selective ER downregulator fulvestrant would be more efficacious than fulvestrant alone in ER-positive metastatic breast cancer resistant to aromatase inhibitor (AI) therapy. Patients and Methods This randomized, double-blind, placebo-controlled, phase II study included 131 postmenopausal women with ER-positive, human epidermal growth factor receptor 2-negative, AI-resistant metastatic breast cancer randomly assigned to fulvestrant (500 mg days 1 and 15 of cycle 1, then day 1 of cycles 2 and beyond) plus everolimus or placebo. The study was designed to have 90% power to detect a 70% improvement in median progression-free survival from 5.4 months to 9.2 months. Secondary end points included objective response and clinical benefit rate (response or stable disease for at least 24 weeks). Prophylactic corticosteroid mouth rinses were not used. Results The addition of everolimus to fulvestrant improved the median progression-free survival from 5.1 to 10.3 months (hazard ratio, 0.61 [95% CI, 0.40 to 0.92]; stratified log-rank P = .02), indicating that the primary trial end point was met. Objective response rates were similar (18.2% v 12.3%; P = .47), but the clinical benefit rate was significantly higher in the everolimus arm (63.6% v 41.5%; P = .01). Adverse events of all grades occurred more often in the everolimus arm, including oral mucositis (53% v 12%), fatigue (42% v 22%), rash (38% v 5%), anemia (31% v. 6%), diarrhea (23% v 8%), hyperglycemia (19% v 5%), hypertriglyceridemia (17% v 3%), and pneumonitis (17% v 0%), although grade 3 to 4 events were uncommon. Conclusion Everolimus enhances the efficacy of fulvestrant in AI-resistant, ER-positive metastatic breast cancer.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Kornblum N, Zhao F, Manola J, et al. Randomized Phase II Trial of Fulvestrant Plus Everolimus or Placebo in Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy: Results of PrE0102. J Clin Oncol. 2018. PMID: 29664714. doi:10.1200/JCO.2017.76.9331

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。